Plerixafor
Other Immunostimulants
Sold as Mozobil
- Drug class
- Other Immunostimulants
- Availability
- Prescription only
- Routes
- Subcutaneous
- Markets covered
- 4
- Products on record
- 17
- FDA reports (12 mo)
- 84
Overview
Plain-language summary, compiled from the cited regulatory records
Plerixafor is a medication classified as an other immunostimulant [1]. It is approved for use in combination with filgrastim to help mobilize hematopoietic stem cells (HSCs) from the bone marrow into the peripheral blood [1]. These mobilized stem cells can then be collected for autologous transplantation [1]. This treatment is indicated for patients diagnosed with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) [1].
Plerixafor is available under the brand name Mozobil [1]. In the past 12 months, there have been 84 adverse event reports associated with this active ingredient [2]. Common adverse events reported include plasma cell myeloma, thrombocytopenia, death, febrile neutropenia, and neutropenia [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 11 | May 22, 2026 |
| CA Canada | Health Canada | 3 | March 22, 2025 |
| EU European Union | EMA | 2 | July 31, 2024 |
| US United States | FDA | 1 | September 22, 2025 |
GBUnited Kingdom· MHRA
11 products
Uses
2). 2)
How to take
CACanada· Health Canada
3 products
Uses
Adult Plerixafor Injection (plerixafor) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to: • mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).
Some patients with NHL and MM are able to meet minimal and target HSC collection criteria with G-CSF alone (see 14 CLINICAL TRIALS). Pediatric (1 to less than 18 years of age) Plerixafor Injection is indicated in combination with G-CSF to enhance mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumors and either: • low circulating stem cell count on the predicted date of collection after mobilization with G-CSF (with or without chemotherapy), or • who previously failed to collect sufficient hematopoietic stem cells (see 4 DOSAGE AND ADMINISTRATION).
EUEuropean Union· EMA
2 products
Uses
2). 2).
How to take
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE Mozobil is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM).
Mozobil, a hematopoietic stem cell mobilizer, is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma.
( 1 )
How to take
Sources & citations
- [1]MHRA (UK) · PL002400599 · revised January 13, 2025
- [2]Health Canada (DPD) · 02529815 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/001030 · revised July 31, 2024
- [4]FDA DailyMed · 0ed08d2b-5051-46… · revised September 22, 2025 [PDF]
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.